Here are three things to know.
1. Viralytics, a Sydney, Australia-based biotech company, uses viruses to detect and kill cancer cells.
2. Under the terms of the deal, Merck will pay 1.75 Australian dollars ($1.37) per share for the company.
3. “We are eager to further build on Viralytics’s science as we continue our efforts to harness the immune system to improve long-term disease control and survival outcomes for people with cancer,” Roy Baynes, MD, PhD, senior vice president and head of global clinical development, CMO of Merck Research Laboratories, said in a press release.
More articles on supply chain:
Amazon quietly launches exclusive OTC product line: 7 things to know
AbbVie, Voyager ink $69M deal to develop Alzheimer’s drug
Roche’s diabetes app recalled over software bug: 4 things to know
